Combination of mutated herpes simplex virus type 1 (G207 virus) with radiation for the treatment of squamous cell carcinoma of the head and neck

2005 ◽  
Vol 41 (2) ◽  
pp. 313-322 ◽  
Author(s):  
Se-Heon Kim ◽  
Richard J. Wong ◽  
David A. Kooby ◽  
John F. Carew ◽  
Prasad S. Adusumilli ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Herpes Simplex Virus ◽  
Herpes Simplex ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Virus Type ◽  
Squamous Cell ◽  
Herpes Simplex Virus Type ◽  
Simplex Virus

A comparative review of the potential role of adenovirus and Herpes Simplex Virus in the treatment of advanced squamous cell carcinoma of the head and neck

2009 ◽  
Vol 8 (3) ◽  
pp. 147-155
Author(s):  
Stuart McCaighy
Keyword(s):  
Immune Response ◽  
Squamous Cell Carcinoma ◽  
Herpes Simplex Virus ◽  
Herpes Simplex ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Phase Iii ◽  
Advanced Squamous Cell Carcinoma ◽  
Simplex Virus

AbstractThe unsatisfactory outcome of patients who receive intensive multimodality treatment for advanced squamous cell carcinoma of the head and neck (SCCHN) has motivated investigators to seek novel treatments to improve survival. Advances in molecular biology has led to the development of cancer gene therapy (CGT) and revived interest in viral vectors as a mechanism. SCCHN is an ideal model for CGT as disease remains locoregional and is amenable to injection of viruses. Adenovirus and Herpes Simplex Virus Type-1 (HSV) are the most studied Oncolytic Viruses (OVs). Both viruses have been shown to select and replicate in tumour cells and demonstrate anti-tumour effect in laboratory studies and clinical trials. Toxicity from OVs is minor and manageable. Different adenoviral mutants have been investigated with mixed responses. One vector, H101, has now been licensed after showing significant tumour regression in conjunction with chemotherapy. HSV has a larger capacity to carry genetic material and with the addition of the granulocyte–macrophage colony–stimulating factor, has the potential to stimulate an immune response systemically and at the site of disease. OVs are limited by the distribution of virus beyond injection site and by pre-existing or rapidly established immune response. Phase III studies are required.

Intratumoral injection of herpes simplex virus HF10 in recurrent head and neck squamous cell carcinoma

2006 ◽  
Vol 126 (10) ◽  
pp. 1115-1117 ◽  
Author(s):  
Yasushi Fujimoto ◽  
Terukazu Mizuno ◽  
Saiko Sugiura ◽  
Fumi Goshima ◽  
Shin-Ichi Kohno ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Herpes Simplex Virus ◽  
Herpes Simplex ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Intratumoral Injection ◽  
Neck Squamous Cell Carcinoma ◽  
Simplex Virus ◽  
Recurrent Head

Efficient gene transfer to human squamous cell carcinomas by the herpes simplex virus type 1 amplicon vector

1998 ◽  
Vol 176 (5) ◽  
pp. 404-408 ◽  
Author(s):  
John F. Carew ◽  
Howard Federoff ◽  
Marc Halterman ◽  
Dennis H. Kraus ◽  
Howard Savage ◽  
...  
Keyword(s):  
Herpes Simplex Virus ◽  
Herpes Simplex ◽  
Gene Transfer ◽  
Virus Type ◽  
Squamous Cell ◽  
Herpes Simplex Virus Type ◽  
Squamous Cell Carcinomas ◽  
Efficient Gene ◽  
Simplex Virus

scholarly journals Distribution of Herpes Simplex Virus Type 1 and Varicella Zoster Virus in Ganglia of the Human Head and Neck

2009 ◽  
Vol 200 (12) ◽  
pp. 1901-1906 ◽  
Author(s):  
Elizabeth R. Richter ◽  
James K. Dias ◽  
James E. Gilbert II ◽  
Sally S. Atherton
Keyword(s):  
Herpes Simplex Virus ◽  
Herpes Simplex ◽  
Head And Neck ◽  
Varicella Zoster Virus ◽  
Virus Type ◽  
Herpes Simplex Virus Type ◽  
Human Head ◽  
Varicella Zoster ◽  
Simplex Virus
Sign in / Sign up

Export Citation Format

Share Document